Ideas

Extracorporeal shockwave therapy for Lifespan extension: Extracorporeal shockwave therapy prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 22/June/2017, 11.32 pm
Extracorporeal shockwave therapy for Lifespan extension: Extracorporeal shockwave therapy prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 22/June/2017, 11.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: It has been shown earlier that antagonizing angiotensin II type I receptor (AT1R) expression may prolong mammalian life span. Further, it has been shown that disruption of AT1R (AGTR1)…

read more

Extracorporeal Shock wave therapy for ageing-associated diseases: Extracorporeal Shock wave therapy increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 22/June/2017, 11.30 pm
Extracorporeal Shock wave therapy for ageing-associated diseases: Extracorporeal Shock wave therapy increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 22/June/2017, 11.30 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Bio-Magnetic therapy for KRAS/LKB1-mutant lung cancer: Low frequency magnetic field increases the levels of tumor suppressor proteins, inhibits the expression of urea cycle enzyme carbamoyl phosphate synthetase-1 (CSP1), decreases pyrimidine pools, stalls DNA synthesis, and inhibits the progression of KRAS/LKB1-mutated lung cancers via up regulation of its target gene, 21/June/2017, 11.29 pm
Bio-Magnetic therapy for KRAS/LKB1-mutant lung cancer: Low frequency magnetic field increases the levels of tumor suppressor proteins, inhibits the expression of urea cycle enzyme carbamoyl phosphate synthetase-1 (CSP1), decreases pyrimidine pools, stalls DNA synthesis, and inhibits the progression of KRAS/LKB1-mutated lung cancers via up regulation of its target gene, 21/June/2017, 11.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Children’s Medical Center Research Institute, UT Southwestern Medical Center, Dallas, Texas 75390, USA; Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas…

read more

Natural product therapy for CyclinD3-CDK6-overexpressing cancers: Honokiol, isolated from Magnolia Grandiflora(MG), increases the levels of tumor suppressor proteins, inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 21/June/2017, 11.22 pm
Natural product therapy for CyclinD3-CDK6-overexpressing cancers: Honokiol, isolated from Magnolia Grandiflora(MG), increases the levels of tumor suppressor proteins, inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 21/June/2017, 11.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA shows that “The…

read more

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): Isorhapontigenin, isolated from Norway/Sitka spruce, decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 21/June/2017, 11.17 pm
Natural product-derived therapy for Chronic Myeloid leukaemia (CML): Isorhapontigenin, isolated from Norway/Sitka spruce, decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 21/June/2017, 11.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; and The University of…

read more

Natural product-derived therapy for heart regeneration and repair: Myricitrin, isolated from Myrica rubra, increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 21/June/2017, 11.08 pm
Natural product-derived therapy for heart regeneration and repair: Myricitrin, isolated from Myrica rubra, increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 21/June/2017, 11.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more
Start Typing